Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HILPDA antisense RNA 1 (HILPDA-AS1) is a long non-coding RNA (lncRNA) gene affiliated with the antisense class of RNA molecules. It is transcribed from the DNA strand opposite to the protein-coding HILPDA gene. Like other antisense lncRNAs, HILPDA-AS1 is presumed to regulate the expression of its sense counterpart (HILPDA), potentially through mechanisms such as transcriptional interference, RNA-RNA hybrid formation, or chromatin remodeling, although direct functional studies have not been reported. No evidence suggests HILPDA-AS1 is itself a direct therapeutic target, nor has it been described as a drug target, disease biomarker, or safety concern. The gene is cataloged in reference databases (Ensembl: ENSG00000240758, HGNC: 55641). If you intended to refer to the protein-coding gene HILPDA (Hypoxia-inducible lipid droplet-associated protein), that is a distinct protein involved in lipid metabolism and disease, and is considered a therapeutic target in metabolic disease and cancer contexts[1][4][5][6][8], but HILPDA-AS1 itself is a non-coding RNA gene, not a protein or established therapeutic target.
Not established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HILPDA antisense RNA 1 (HILPDA-AS1).